Monday, March 23, 2009

Laquinimod Bravo Study Announcement from Rocky Mountain MS Center

Dear Friend of the Rocky Mountain MS Center,

We know that patients with multiple sclerosis (MS) want more options. So do we. Please help us get the word out about an investigational oral drug, laquinimod.If you know someone who has confirmed relapsing-remitting MS (RRMS), is between the ages of 18 and 55, has never been treated with interferon medications (Avonex®, Betaseron® or Rebif®) and may have had at least one relapse in the last 12 months (or two relapses in the last 24 months), this Bravo study may be a good fit.

To see if there is a study site in your area, please visit

If there is a site in your area, please note the reference code RMMSC when contacting it. Trial coordinators are standing by to help determine eligibility.

Karen WenzelExecutive Director

No comments:

Post a Comment